A5020981865- Peptidase Inhibition and Analysis
- Cancer, Stress, Anesthesia, and Immune Response
- Neuropeptides and Animal Physiology
- Research on Leishmaniasis Studies
- Immunotherapy and Immune Responses
- Helminth infection and control
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Malaria Research and Control
- Ubiquitin and proteasome pathways
- Prostate Cancer Treatment and Research
- Cancer Research and Treatments
- Parasites and Host Interactions
- Protein Degradation and Inhibitors
- Insect Resistance and Genetics
- Immune Cell Function and Interaction
- Genetics and Neurodevelopmental Disorders
- Invertebrate Immune Response Mechanisms
- Mast cells and histamine
- PARP inhibition in cancer therapy
- Neutropenia and Cancer Infections
- Blood disorders and treatments
- Food Allergy and Anaphylaxis Research
- Hematopoietic Stem Cell Transplantation
- Mosquito-borne diseases and control
University of Nottingham
2018-2022
Medical Research Council
2019
University of Leicester
2019
Wellcome Centre for Molecular Parasitology
2018
University of Glasgow
2018
Targeting parasite's protein kinase Malaria elimination goals are constantly eroded by the challenge of emerging drug and insecticide resistance. Alam et al. have taken established targets—CLK kinases involved in regulation RNA splicing—and investigated how inhibition enzymes blocks completion its complex life cycle. They identified an inhibitor CLK that was 100-fold less active against most closely related human effective at clearing rodent malaria parasites. Not only does this compound...
Abstract Purpose: CD137 is a T- and NK-cell costimulatory receptor involved in consolidating immunologic responses. The potent agonist urelumab has shown clinical promise as cancer immunotherapeutic but development been hampered by on-target off-tumor toxicities. A targeted to the prostate-specific membrane antigen (PSMA), frequently highly expressed on castration-resistant metastatic prostate (mCRPC) tumor cells, could bring effective immunotherapy this immunologically challenging address...
Chemotherapy-induced hemorrhagic cystitis is characterized by bladder pain and voiding dysfunction caused hemorrhage inflammation. Novel therapeutic options to treat are needed. We previously reported that systemic administration of the Schistosomiasis hematobium-derived protein H-IPSEH06 (IL-4-inducing principle from Schistosoma mansoni eggs) superior three doses MESNA in alleviating (Mbanefo EC, Le L, Pennington LF, Odegaard JI, Jardetzky TS, Alouffi A, Falcone FH, Hsieh MH. FASEB J 32:...
Abstract The requirement for next generation anti-malarials to be both curative and transmission blockers necessitate the identification of molecular pathways essential viability asexual sexual parasite life stages. Here we identify a selective inhibitor Plasmodium falciparum protein kinase Pf CLK3 which use in combination with chemogenetics, whole genome sequencing transcriptomics validate as druggable target acting at multiple Consistent proposed role regulator RNA splicing, inhibition...
Abstract INTRODUCTION: CD137 is a T and NK cell costimulatory receptor involved in consolidating immunological responses. The potent agonist urelumab has shown clinical promise as cancer immunotherapeutic but development been hampered by on-target off-tumour toxicities. A targeted to the prostate-specific membrane antigen (PSMA), frequently highly expressed on castration-resistant metastatic prostate (mCRPC) tumour cells, could bring effective immunotherapy this immunologically challenging...
<p>Supplementary Figure 8: Spheroid end-of-study T=240h images</p>
<p>Supplementary Figure 9: Neuroendocrine Differentiation Phenotypes in Prostate Cancer Liver Metastases</p>
<p>Supplementary Figure 10: hPSMA expression on RP1 tumour cells is lost over time, even in tumours dosed with HSA only</p>
<p>Supplementary Figure 9: Neuroendocrine Differentiation Phenotypes in Prostate Cancer Liver Metastases</p>
<div>AbstractPurpose:<p>CD137 is a T- and NK-cell costimulatory receptor involved in consolidating immunologic responses. The potent CD137 agonist urelumab has shown clinical promise as cancer immunotherapeutic but development been hampered by on-target off-tumor toxicities. A targeted to the prostate-specific membrane antigen (PSMA), frequently highly expressed on castration-resistant metastatic prostate (mCRPC) tumor cells, could bring effective immunotherapy this...
<p>Supplemental Methods</p>
<p>Supplementary Figure 3: PK/TK dosing strategies</p>
<p>Supplementary Figure 8: Spheroid end-of-study T=240h images</p>
<p>Supplementary Figure 11: Vipivotide tetraxetan does not interfere with CB307 activity</p>
<p>Supplementary Figure 5: CB307 binding to cell-presented targets</p>
<p>Supplementary Figure 5: CB307 binding to cell-presented targets</p>
<p>Supplementary Figure 1: Validation of CD137 immunohistochemistry</p>
<p>Supplementary Figure 7: CRISPR-mediated PD-L1 gene knock-out in DU145-PSMA cells</p>
<p>Supplementary Figure 1: Validation of CD137 immunohistochemistry</p>
<div>AbstractPurpose:<p>CD137 is a T- and NK-cell costimulatory receptor involved in consolidating immunologic responses. The potent CD137 agonist urelumab has shown clinical promise as cancer immunotherapeutic but development been hampered by on-target off-tumor toxicities. A targeted to the prostate-specific membrane antigen (PSMA), frequently highly expressed on castration-resistant metastatic prostate (mCRPC) tumor cells, could bring effective immunotherapy this...
<p>Supplemental Methods</p>
<p>Supplementary Figure 10: hPSMA expression on RP1 tumour cells is lost over time, even in tumours dosed with HSA only</p>
<p>Supplementary Video 1</p>
<p>Supplementary Figure 7: CRISPR-mediated PD-L1 gene knock-out in DU145-PSMA cells</p>